Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

The prevalence and factors associated with aspirin resistance in patients premedicated with aspirin.

Al-Azzam SI, Alzoubi KH, Khabour O, Alowidi A, Tawalbeh D.

Acta Cardiol. 2012 Aug;67(4):445-8.

PMID:
22997999
2.

Prevalence of aspirin resistance in patients with type 2 diabetes.

Fateh-Moghadam S, Plöckinger U, Cabeza N, Htun P, Reuter T, Ersel S, Gawaz M, Dietz R, Bocksch W.

Acta Diabetol. 2005 Jun;42(2):99-103.

PMID:
15944844
3.

Antiplatelet effect of aspirin in patients with coronary artery disease.

Grove EL.

Dan Med J. 2012 Sep;59(9):B4506. Review.

PMID:
22951204
4.

The contribution of platelet glycoproteins (GPIa C807T and GPIba C-5T) and cyclooxygenase 2 (COX-2G-765C) polymorphisms to platelet response in patients treated with aspirin.

Al-Azzam SI, Alzoubi KH, Khabour OF, Tawalbeh D, Al-Azzeh O.

Gene. 2013 Sep 10;526(2):118-21. doi: 10.1016/j.gene.2013.04.083. Epub 2013 May 18.

PMID:
23688555
5.

Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors.

Salama MM, Morad AR, Saleh MA, Sabri NA, Zaki MM, ElSafady LA.

J Clin Pharm Ther. 2012 Dec;37(6):630-6. doi: 10.1111/j.1365-2710.2009.01083.x. Epub 2009 Aug 12.

PMID:
23121257
6.

Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables.

Feher G, Koltai K, Papp E, Alkonyi B, Solyom A, Kenyeres P, Kesmarky G, Czopf L, Toth K.

Drugs Aging. 2006;23(7):559-67.

PMID:
16930084
7.

Factors associated with aspirin resistance in patients premedicated with aspirin and clopidogrel for endovascular neurosurgery.

Reavey-Cantwell JF, Fox WC, Reichwage BD, Fautheree GL, Velat GJ, Whiting JH, Chi YY, Hoh BL.

Neurosurgery. 2009 May;64(5):890-5; discussion 895-6. doi: 10.1227/01.NEU.0000341904.39691.2F.

PMID:
19287328
8.

Evaluation of the effect of angiotensin converting enzyme inhibitors and angiotensin receptors blockers on aspirin antiplatelet effect.

Al-Azzam SI, Alzoubi KH, Khabour OF, Quttina M, Zayadeen R.

Int J Clin Pharmacol Ther. 2016 Feb;54(2):96-101. doi: 10.5414/CP202503.

PMID:
26709600
9.

Prevalence of aspirin resistance measured by PFA-100.

Coma-Canella I, Velasco A, Castano S.

Int J Cardiol. 2005 May 11;101(1):71-6.

PMID:
15860386
10.

Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.

Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A; PPP Collaborative Group.

Diabetes Care. 2003 Dec;26(12):3264-72.

PMID:
14633812
11.

The prevalence, risk factors and prognosis of aspirin resistance in elderly male patients with cardiovascular disease.

Cao J, Liu L, Fan L, Chen T, Hu G, Hu Y, Zhu B, Li J, Wang H, Li X.

Aging Male. 2012 Sep;15(3):140-7. doi: 10.3109/13685538.2012.666584. Epub 2012 Mar 27.

PMID:
22452804
12.

[Frequency and characteristics of aspirin resistance in Chilean cardiovascular patients].

Dussaillant N G, Zapata M M, Fardella B P, Conte L G, Cuneo V M.

Rev Med Chil. 2005 Apr;133(4):409-17. Epub 2005 Jun 8. Spanish.

13.

Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events.

Yi X, Zhou Q, Lin J, Chi L.

Int J Stroke. 2013 Oct;8(7):535-9. doi: 10.1111/j.1747-4949.2012.00929.x. Epub 2012 Dec 11.

PMID:
23231453
14.

Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus.

Ertugrul DT, Tutal E, Yildiz M, Akin O, Yalçin AA, Ure OS, Yilmaz H, Yavuz B, Deveci OS, Ata N, Küçükazman M.

J Clin Endocrinol Metab. 2010 Jun;95(6):2897-901. doi: 10.1210/jc.2009-2392. Epub 2010 Apr 9.

PMID:
20382685
15.

Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease.

Larsen SB, Grove EL, Neergaard-Petersen S, Würtz M, Hvas AM, Kristensen SD.

PLoS One. 2015 May 18;10(5):e0126767. doi: 10.1371/journal.pone.0126767. eCollection 2015.

16.

Factors responsible for "aspirin resistance" - can we identify them?

Postuła M, Tarchalska-Kryńska B, Filipiak KJ, Kosior D, Serafin A, Huczek Z, Opolski G.

Kardiol Pol. 2010 Apr;68(4):403-11; discussion 412-3.

17.

Antiplatelet therapy for primary and secondary prevention in Jordanian patients with diabetes mellitus.

Bulatova NR, Yousef AM, AbuRuz SM.

Thromb Res. 2007;121(1):43-50. Epub 2007 Apr 25.

PMID:
17462716
18.

Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study.

Karolczak K, Kamysz W, Karafova A, Drzewoski J, Watala C.

Pharmacol Res. 2013 Aug;74:7-22. doi: 10.1016/j.phrs.2013.04.010. Epub 2013 May 7.

PMID:
23665469
19.

The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease.

Würtz M, Grove EL, Kristensen SD, Hvas AM.

Heart. 2010 Mar;96(5):368-71. doi: 10.1136/hrt.2009.181107. Epub 2009 Nov 11.

PMID:
19910291
20.

Variability in platelet response to a single daily dose of 150 mg enteric coated aspirin in a high risk population.

Mardikar H, Deo D, Deshpande N, Mardikar M, Ghosh A, Munot K, Steinhubl S, Mukherjee D.

J Assoc Physicians India. 2008 May;56:321-4.

PMID:
18700638

Supplemental Content

Support Center